title: Increased PLA2 activity is not related to increase GLUT1 expression in L6 myotubes under hypoxic conditions.
abstract: Incubation of L6 myotubes for 24 h under hypoxic conditions leads to a 5.8 +/- 1.2 fold increase in 2-deoxyglucose uptake. In those conditions phospholipase A2 is activated, leading to a 2.4 +/- 0.8 fold increased release of arachidonic acid (AA) to the medium, and to 95% increased synthesis of PGF2 alpha but not of PGE2 as compared to cells incubated in normoxic conditions. Under hypoxia, the PLA2 inhibitor bromophenacyl bromide (BPB) inhibited AA release and PGF2 alpha synthesis, yet it did not affect the increase in glucose uptake into L6 myotubes. The amount of GLUT1 immunoreactive proteins in total membranes of hypoxia treated cells was evaluated 5.1 +/- 1.2 fold compared to control cells. Neither 10 microM BPB nor 100 mM aspirin (ASA) prevented this increase in GLUT1 expression. Preincubation of myotubes for either 1 or 23 h with 50 microM exogenous AA, prevented insulin induced 2-deoxyglucose uptake stimulation, suggesting that although AA or one of its metabolites did not regulate the synthesis or stability of GLUT1, it may interfere with the signal transduction of insulin in muscle cells.
authors.affiliation: Pediatric Research Laboratory, Soroka Medical Center, Beer-Sheva, Israel.
authors.forename: N
authors.initials: N
authors.lastname: Kozlovsky
authors.forename: E
authors.initials: E
authors.lastname: Shohami
authors.forename: N
authors.initials: N
authors.lastname: Bashan
mesh_terms: D000098:Acetophenones / Q000494:pharmacology; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001692:Biological Transport / Q000187:drug effects; D015687:Cell Hypoxia; D002460:Cell Line; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D003847:Deoxyglucose / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D051272:Glucose Transporter Type 1; D051275:Glucose Transporter Type 4; D007328:Insulin / Q000494:pharmacology; D008565:Membrane Proteins / Q000378:metabolism; D009004:Monosaccharide Transport Proteins / Q000096:biosynthesis* / Q000378:metabolism; D009124:Muscle Proteins; D018482:Muscle, Skeletal / Q000166:cytology / Q000378:metabolism*; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D011453:Prostaglandins / Q000378:metabolism; D011796:Quinacrine / Q000494:pharmacology; D051381:Rats; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D000098:Acetophenones; D016861:Cyclooxygenase Inhibitors; D051272:Glucose Transporter Type 1; D051275:Glucose Transporter Type 4; D007328:Insulin; D008565:Membrane Proteins; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; D011453:Prostaglandins; C495679:Slc2a1 protein, rat; C495694:Slc2a4 protein, rat; D016718:Arachidonic Acid; D003847:Deoxyglucose; D010741:Phospholipases A; D054467:Phospholipases A2; D011796:Quinacrine; D005947:Glucose; C006821:4-bromophenacyl bromide